Alto Neuroscience Inc. (NYSE: ANRO) is a California-based biopharmaceutical company developing personalised treatments for mental health conditions. It focuses on innovative therapies for major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and schizophrenia, with promising drug candidates like ALTO-100 and ALTO-300. The company is also pioneering a biomarker-based platform to tailor treatments, using patient-specific biological data to improve outcomes. Since its founding in 2019, Alto Neuroscience has been at the forefront of personalised mental health care.
Latest shares articles
Magnificent Seven Earnings Review
The Q1 2025 earnings season for the Magnificent Seven—Apple, Microsoft, Nvidia, Amazon, Alphabet, Meta Platforms, and Tesla—revealed a shared strategic emphasis on artificial intelligence, infrastructure investment, supply chain resilience, and capital discipline.
09:14, 3 June 2025
UK economy outpaces gloomy forecasts, yet caution remains
The UK economy grew more than expected in Q1 despite warnings about a recession, but the outlook remains clouded by the threat of tariffs
08:08, 15 May 2025
Barrick Gold forecast: Third-party price target
Discover the Barrick Gold (GOLD) price predictions for 2025 and beyond, with analyst price targets and more on Capital.com
15:41, 8 May 2025
US stocks hold ground despite Powell’s stagflation warning
US equities continue to attract buying interest backed by improved market sentiment despite Powell's warning about stagflation
11:29, 8 May 2025
Ratings and Reviews
Ratings and Reviews
